These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6825393)

  • 1. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T; Vinks A; Otton SV; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
    Woolhouse NM; Eichelbaum M; Oates NS; Idle JR; Smith RL
    Clin Pharmacol Ther; 1985 May; 37(5):512-21. PubMed ID: 3987174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 10. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
    Inaba T; Tyndale RE; Mahon WA
    Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
    [No Abstract]   [Full Text] [Related]  

  • 13. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 15. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M; Gross AS
    Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
    J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.